MannKind Corporation (NASDAQ:MNKD) stock opened today at $9.17 and is currently trading at $9.20. The stock showed a positive weekly performance of 16.22%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock opened at $6.08, in current trading session and currently is at $6.03, by losing -0.33%. The 52 week range of $4.05 – $9.05. Company’s market capitalization is $1.33 billion.
Spherix Inc (NASDAQ:SPEX) announced that it has completed a $20 million equity financing consisting of 10 million shares of Series J Convertible Preferred Stock (convertible into common stock) at $2 per share to raise gross proceeds of $20 million, before payment of placement agent fees and other expenses of the offering payable by us. No warrants were issued as part of the transaction. Spherix Inc (NASDAQ:SPEX) stock is open at $1.99 and currently trading at $1.94. The EPS of the stock is -12.60. Company’s market capitalization is $23.80 billion.
Pfizer Inc. (NYSE:PFE) agreed to pay $325 million to settle a lawsuit brought by health-care benefit providers who claimed the drugmaker marketed the epilepsy drug Neurontin for unapproved uses. Pfizer Inc. (NYSE:PFE) stock opened the session at $29.77, and now is at $29.65. The 52 week range of the PFE stock remained $27.12 – $32.96 and the day range was $29.58 – $29.83.
On May 29, Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) have been on a rollercoaster ride this year due to mixed updates on the company’s lead pipeline candidate, obeticholic acid (:OCA). Shares of the company were hammered a week ago after a report from The Street disclosed that the company had information about the occurrence of abnormal cholesterol levels in its phase IIb study on OCA when it came out with a press release on Jan 9, 2014. The trial was sponsored and conducted by the National Institute of Diabetes & Digestive & Kidney Diseases (:NIDDK). Intercept Pharmaceuticals Inc (NASDAQ:ICPT) stock is open at $232.94 and currently trading at $231.58. The EPS of the stock is -16.30. Company’s market capitalization is $4.87 billion.